Search Results

CCG-63802 25mg 25mg  | Purity Not Available

Adooq Bioscience

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.

More Information Supplier Page

CCG-63802 10mg 10mg  | Purity Not Available

Adooq Bioscience

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.

More Information Supplier Page

CB 300919 50mg 50mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 5mg 5mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 25mg 25mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 10mg 10mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page